Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy-Reference-Cited by-同舟云学术

Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy

Published:2024 Issue:1 Volume:60 Page:69
ISSN:2233-7385
Container-title:Chonnam Medical Journal
language:en
Short-container-title:Chonnam Med J

Author:

Choi Hyun-Woo¹,Jung Younggon²,Kim Uh Jin³,Lee Sang-Cheol⁴,Kwon Jung Hye⁵⁶,Kim Hyeonjong³,Kim Sarah³,Lee Yoonjung³,Shim Hyun-Jung³,Cho Sang-Hee³,Chung Ik-Joo³,Hwang Eu Chang⁷,Kang Seung Ji³,Bae Woo Kyun³,Kee Seung-Jung¹

Affiliation:

1. Department of Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea.

2. Division of Infectious Disease, Department of Internal Medicine, St. Carollo General Hospital, Suncheon, Korea.

3. Department of Internal Medicine, Chonnam National University Medical School, Hwasun, Korea.

4. Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital Cheonan, Cheonan, Korea.

5. Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.

6. Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.

7. Department of Urology, Chonnam National University Medical School, Hwasun, Korea.

Publisher

XMLink

Link

https://cmj.ac.kr/pdf/10.4068/cmj.2024.60.1.69

Reference20 articles.

1. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis

2. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

3. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

4. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

5. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Immunological Alertness and Response to COVID-19 Vaccination—Conditions for Prevention in Early Palliative Oncological Care Patients;Vaccines;2024-03-13